Summary of Significant Accounting Policies - Narrative (Details)			1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 24, 2015	May. 16, 2014	Dec. 31, 2014 USD ($)	May. 31, 2014	Sep. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2015 USD ($) customer subassembly segment	Dec. 31, 2014 USD ($) $ / shares	Dec. 31, 2013 USD ($)
Concentration Risk [Line Items]
Loss on sale of investments							$ 5,746,000
Period to accept returned unused product after product expiration							1 year
Impairment of long-lived assets							$ 0	$ 838,000	$ 0
Increase in product returns estimate									3,634,000
Change in estimate, effect on earnings per share | $ / shares								$ 0.24
Sales reserve revenues							1,967,000
Advertising expense							6,000	$ 333,000	313,000
Foreign currency gains (losses)							$ (127,000)	(145,000)	$ (95,000)
Number of operating segments | segment							1
Zohydro ER [Member]
Concentration Risk [Line Items]
Restricted cash and cash equivalents							$ 10,002,000
Potential indemnification period	12 months
Impairment of long-lived assets					$ 5,485,000
Sumavel DosePro [Member]
Concentration Risk [Line Items]
Restricted cash and cash equivalents			$ 8,500,000					$ 8,500,000
Potential indemnification period		12 months		12 months
Impairment of long-lived assets						$ 838,000
Cost of goods sold mark-up, in percent		2.50%		2.50%
Contract Manufacturing [Member] | Sales Revenue, Product Line [Member]
Concentration Risk [Line Items]
Number of customers | customer							1
Sumavel DosePro [Member]
Concentration Risk [Line Items]
Period to accept returned unused product after product expiration							1 year
Period to accept returned unused product before expiration							6 months
Product shelf life							30 months
Number of subassemblies | subassembly							2
Zohydro ER and Sumavel DosePro [Member]
Concentration Risk [Line Items]
Period to accept returned unused product after product expiration							12 months
Period to accept returned unused product before expiration							6 months
Endo Ventures Supply Agreement [Member] | Minimum [Member]
Concentration Risk [Line Items]
Term of agreement			8 years
Other Current Assets [Member]
Concentration Risk [Line Items]
Receivables from unsettled sales of short-term investments							$ 498,000